Shows / Multiple Myeloma Hub
Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Episodes
- Multiple Myeloma Hub
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Ostrava, CZ…
- Multiple Myeloma Hub
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina…
- Multiple Myeloma Hub
The role of consolidation after autologous stem cell transplantation
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria…
- Multiple Myeloma Hub
What are the pros and cons of bispecific antibodies for multiple myeloma?
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The…
- Multiple Myeloma Hub
Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca…
- Multiple Myeloma Hub
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US…
- Multiple Myeloma Hub
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje…
- Multiple Myeloma Hub
Should 'cure' be the goal for multiple myeloma?
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the…
- Multiple Myeloma Hub
Treating elderly and frail patients with MM: Cure versus disease control
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the…
- Multiple Myeloma Hub
Is transplantation still relevant? If yes, in what context?
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the…
- Multiple Myeloma Hub
The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Columbia…
- Multiple Myeloma Hub
Is the treatment of high-risk SMM the way for achieving the cure?
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the…
- Multiple Myeloma Hub
Does 'cure' have a different meaning in MM?
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the…
- Multiple Myeloma Hub
How to treat first relapse in lenalidomide-refractory MM?
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How…
- Multiple Myeloma Hub
With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results…
- Multiple Myeloma Hub
When BCMA-directed therapy is not an option, how should we treat late relapse?
During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu…
- Multiple Myeloma Hub
What do you need to remember when facing CAR T-cell toxicities?
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US…
- Multiple Myeloma Hub
What are the key additions to the new NCCN guidelines for multiple myeloma?
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of…
- Multiple Myeloma Hub
If maintenance after induction reduces therapy options at relapse, is it still worth it?
During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, and…
- Multiple Myeloma Hub
New findings on the role of the immune microenvironment presented at ASH 2020
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Elisabet E. Manasanch, MD Anderson Cancer…
- Multiple Myeloma Hub
ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Francesca Gay (University of Turin…
- Multiple Myeloma Hub
Should we still use high-dose melphalan in the era of novel agents?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Cancer…
- Multiple Myeloma Hub
What are the unmet needs in AL amyloidosis in Europe?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Efstathios Kastritis, National and…
- Multiple Myeloma Hub
ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc Braunstein, NYU Langone Health, New…
- Multiple Myeloma Hub
Can single cell sequencing help to better define and monitor MM?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Maximilian Merz, Heidelberg University…
- Multiple Myeloma Hub
My experience with novel immunotherapies
During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to speak to…
- Multiple Myeloma Hub
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MM Hub was pleased to speak to Christine Spencer, Parker Institute for…
- Multiple Myeloma Hub
Melphalan flufenamide (melflufen) + novel agents for RRMM
During COMy 2020, Multiple Myeloma Hub Steering Committee Member Paul Richardson, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub…
- Multiple Myeloma Hub
Isatuximab plus KRd for high-risk NDMM
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Cancer Center…
- Multiple Myeloma Hub
Novel approaches in multiple myeloma: what is unique about CELMoDs?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farber Cancer…
- Multiple Myeloma Hub
Hot topics in MM: quadruplets and anti-BCMA therapy
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub was pleased to speak to Saad Usmani, Levine Cancer Institute…
- Multiple Myeloma Hub
Genomics of high-risk myeloma
During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM. Here, Nikhil…
- Multiple Myeloma Hub
The association between the diversity of the oral microbiome and PFS
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhelminen…
- Multiple Myeloma Hub
Novel approaches in multiple myeloma: BFCR4350A
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of…
- Multiple Myeloma Hub
Updates from the KarMMa trial
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer…
- Multiple Myeloma Hub
Update from CARTITUDE-1 | What's new since ASH?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon Research…
- Multiple Myeloma Hub
Novel approaches in multiple myeloma: TAK-079
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte…
- Multiple Myeloma Hub
Should we use KRd or VRd for patients with NDMM?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester…
- Multiple Myeloma Hub
What is the optimal treatment for bone lesions, including patients with renal insufficiency?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massachusetts…
- Multiple Myeloma Hub
Recent advances in our understanding of myeloma progression
During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, spoke to the MM Hub about the…
- Multiple Myeloma Hub
Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len
During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Valdecilla…
- Multiple Myeloma Hub
How I treat elderly patients with NDMM
During COMy 2020, Paula Rodriguez Otero, Clínica Universidad de Navarra, Pamplona, ES, spoke to the Multiple Myeloma (MM) Hub. We asked: How should we treat…
- Multiple Myeloma Hub
Understanding resistance mechanisms to current standard of care and how to overcome them
During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mechanisms to…
- Multiple Myeloma Hub
What is plasma cell leukemia and what are the latest advances in treatment?
During COMy 2020, Artur Jurczyszyn, Jagiellonian University Medical College, Krakow, PL, spoke to the Multiple Myeloma Hub. We asked: What is plasma cell…